Advances of blood cell‐based drug delivery systems

&NA; Blood cells, including erythrocytes, leukocytes and platelets are used as drug carriers in a wide range of applications. They have many unique advantages such as long life‐span in circulation (especially erythrocytes), target release capacities (especially platelets), and natural adhesive properties (leukocytes and platelets). These properties make blood cell based delivery systems, as well as their membrane‐derived carriers, far superior to other drug delivery systems. Despite the advantages, the further development of blood cell‐based delivery systems was hindered by limitations in the source, storage, and mass production. To overcome these problems, synthetic biomaterials that mimic blood cell and nanocrystallization of blood cells have been developed and may represent the future direction for blood cell membrane‐based delivery systems. In this paper, we review recent progress of the rising blood cell‐based drug delivery systems, and also discuss their challenges and future tendency of development. Graphical abstract Figure. No caption available.

[1]  Samir Mitragotri,et al.  Platelet-like Nanoparticles: Mimicking Shape, Flexibility, and Surface Biology of Platelets To Target Vascular Injuries , 2014, ACS nano.

[2]  I. Stamenkovic,et al.  Redirection of tumor metastasis by expression of E-selectin in vivo , 1996, The Journal of experimental medicine.

[3]  Michael R. King,et al.  Stem Cell Enrichment with Selectin Receptors: Mimicking the pH Environment of Trauma , 2013, Sensors.

[4]  E. Choi,et al.  Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. , 2012, Biomaterials.

[5]  Andrea Falini,et al.  Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. , 2008, Cancer cell.

[6]  Ronnie H. Fang,et al.  A biomimetic nanosponge that absorbs pore-forming toxins , 2013, Nature nanotechnology.

[7]  M. Arévalo,et al.  Encapsulation and In Vitro Evaluation of Amikacin-Loaded Erythrocytes , 2005, Drug delivery.

[8]  E. Grilli,et al.  Vaccination of Lactating Dairy Cows for the Prevention of Aflatoxin B1 Carry Over in Milk , 2011, PloS one.

[9]  Mehrdad Hamidi,et al.  Carrier Erythrocytes: An Overview , 2003, Drug delivery.

[10]  Gianluca Damonte,et al.  Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study , 2008, The American Journal of Gastroenterology.

[11]  D. Irvine,et al.  Bio-inspired, bioengineered and biomimetic drug delivery carriers , 2011, Nature Reviews Drug Discovery.

[12]  Yi-xiao Luo,et al.  Monocyte mediated brain targeting delivery of macromolecular drug for the therapy of depression. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[13]  A. Voigt,et al.  In vitro inhibition of fungal activity by macrophage-mediated sequestration and release of encapsulated amphotericin B nanosupension in red blood cells. , 2010, Small.

[14]  Ronnie H. Fang,et al.  Nanoparticle-detained toxins for safe and effective vaccination , 2013, Nature nanotechnology.

[15]  D. Hammer,et al.  Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes. , 2002, Biomaterials.

[16]  N. Marsden,et al.  Accumulation of Dextran in Human Red Cells after Hæmolysis , 1959, Nature.

[17]  G S Kansas,et al.  Selectins and their ligands: current concepts and controversies. , 1996, Blood.

[18]  Anne L. van de Ven,et al.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.

[19]  V. Muzykantov,et al.  Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. , 2010, Blood.

[20]  V R Muzykantov,et al.  Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor. , 1995, The Biochemical journal.

[21]  S. Neau,et al.  Biochemically altered human erythrocytes as a carrier for targeted delivery of primaquine: an In Vitro study , 2011, Archives of pharmacal research.

[22]  B. Fanburg,et al.  Reactive oxygen species in cell signaling. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[23]  M. Magnani,et al.  Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Dong-Ming Huang,et al.  Versatile RBC-derived vesicles as nanoparticle vector of photosensitizers for photodynamic therapy. , 2013, Nanoscale.

[25]  R. Flaumenhaft,et al.  Advances in platelet granule biology , 2013, Current opinion in hematology.

[26]  K. Nagashima,et al.  Identification of a Key Target Sequence To Block Human Immunodeficiency Virus Type 1 Replication within thegag-pol Transframe Domain , 2000, Journal of Virology.

[27]  J. Degen,et al.  Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. , 2005, Blood.

[28]  Mauro Magnani,et al.  Approaches to erythrocyte-mediated drug delivery , 2014, Expert opinion on drug delivery.

[29]  V. Muzykantov,et al.  Directed targeting of immunoerythrocytes provides local protection of endothelial cells from damage by hydrogen peroxide. , 1987, The American journal of pathology.

[30]  D. Kaplan,et al.  Characteristics of platelet gels combined with silk. , 2014, Biomaterials.

[31]  Tak Yee Aw,et al.  Reactive oxygen species, cellular redox systems, and apoptosis. , 2010, Free radical biology & medicine.

[32]  D. Hammer,et al.  Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes II: effect of degradation on targeting activity. , 2005, Biomaterials.

[33]  M. Magnani,et al.  Long-term Treatment With Autologous Red Blood Cells Loaded With Dexamethasone 21–Phosphate in Pediatric Patients Affected by Steroid-dependent Crohn Disease , 2007, Journal of pediatric gastroenterology and nutrition.

[34]  N Crawford,et al.  Reversible electropermeabilisation of human and rat blood platelets: evaluation of morphological and functional integrity 'in vitro' and 'in vivo'. , 1989, Biochimica et biophysica acta.

[35]  A. Plebani,et al.  Intra-Erythrocyte Infusion of Dexamethasone Reduces Neurological Symptoms in Ataxia Teleangiectasia Patients: Results of a Phase 2 Trial , 2014, Orphanet Journal of Rare Diseases.

[36]  Vladimir R Muzykantov,et al.  The Glycocalyx Protects Erythrocyte-Bound Tissue-Type Plasminogen Activator from Enzymatic Inhibition , 2007, Journal of Pharmacology and Experimental Therapeutics.

[37]  Yingyu Chen,et al.  Lentivirus‐mediated platelet gene therapy of murine hemophilia A with pre‐existing anti‐factor VIII immunity , 2012, Journal of thrombosis and haemostasis : JTH.

[38]  Dong Wang,et al.  Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma. , 2015, ACS nano.

[39]  M. Innocenti,et al.  The use of autologous blood-derived growth factors in bone regeneration. , 2011, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[40]  L. Zolla,et al.  Encapsulation of proteins into human erythrocytes: a kinetic investigation. , 1990, Biochimica et biophysica acta.

[41]  Robert Gurny,et al.  Current methods for attaching targeting ligands to liposomes and nanoparticles. , 2004, Journal of pharmaceutical sciences.

[42]  QUAN LIU,et al.  Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[43]  G. Gardos.  Connection between membrane adenosinetriphosphatase activity and potassium transport in erythrocyte ghosts , 1964, Experientia.

[44]  Liangfang Zhang,et al.  Anticancer agents: Unleash the forces within. , 2012, Nature chemistry.

[45]  Mehrdad Hamidi,et al.  Co-encapsulation of a drug with a protein in erythrocytes for improved drug loading and release: phenytoin and bovine serum albumin (BSA). , 2011, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[46]  S. Israels,et al.  Platelet dense granules: structure, function and implications for haemostasis. , 1999, Thrombosis research.

[47]  V. Muzykantov,et al.  Avidin attachment to biotinylated amino groups of the erythrocyte membrane eliminates homologous restriction of both classical and alternative pathways of the complement , 1993, FEBS letters.

[48]  L. Hersh,et al.  In vitro and in vivo degradation of Aβ peptide by peptidases coupled to erythrocytes , 2007, Peptides.

[49]  K. Griendling,et al.  Reactive oxygen species in the vasculature: molecular and cellular mechanisms. , 2003, Hypertension.

[50]  Dezhi Ni,et al.  Programmed co-delivery of paclitaxel and doxorubicin boosted by camouflaging with erythrocyte membrane. , 2015, Nanoscale.

[51]  J. M. Lanao,et al.  Drug, enzyme and peptide delivery using erythrocytes as carriers. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[52]  M. King,et al.  Physical Biology in Cancer. 3. The role of cell glycocalyx in vascular transport of circulating tumor cells , 2013, American journal of physiology. Cell physiology.

[53]  M. Rubner,et al.  Bioactive polyelectrolyte multilayers: hyaluronic acid mediated B lymphocyte adhesion. , 2010, Biomacromolecules.

[54]  Vasili Karas,et al.  Platelet-rich plasma: a milieu of bioactive factors. , 2012, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.

[55]  J. Olsen,et al.  Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. , 2000, Blood.

[56]  G P Samokhin,et al.  Targeting of enzyme immobilized on erythrocyte membrane to collagen‐coated surface , 1985, FEBS letters.

[57]  M. Hamidi,et al.  Preparation and in vitro characterization of carrier erythrocytes for vaccine delivery. , 2007, International journal of pharmaceutics.

[58]  Feng Gao,et al.  Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. , 2014, ACS nano.

[59]  Jing Huo,et al.  Slow release properties and liver‐targeting characteristics of methotrexate erythrocyte carriers , 2009, Fundamental & clinical pharmacology.

[60]  G. Damonte,et al.  Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain , 2009, Journal of drug targeting.

[61]  J. Hamlin,et al.  -Galactosidase: immunological activity of ribosome-bound, growing polypeptide chains. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[62]  A. Dasgupta,et al.  Drug Delivery Using Platelet Cancer Cell Interaction , 2013, Pharmaceutical Research.

[63]  G. Golomb,et al.  Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[64]  H. Dombret,et al.  l‐asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005‐01 randomized trial , 2011, British journal of haematology.

[65]  F. Ahsan,et al.  Nano-Engineered Erythrocyte Ghosts as Inhalational Carriers for Delivery of Fasudil: Preparation and Characterization , 2014, Pharmaceutical Research.

[66]  Ronnie H. Fang,et al.  Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform , 2011, Proceedings of the National Academy of Sciences.

[67]  R. Gaudreault,et al.  Erythrocyte membrane-bound daunorubicin as a delivery system in anticancer treatment. , 1989, Anticancer research.

[68]  S. Kesari,et al.  Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[69]  M. Magnani,et al.  Cell-based drug delivery. , 2008, Advanced drug delivery reviews.

[70]  F. Stellacci,et al.  Erythrocyte incubation as a method for free-dye presence determination in fluorescently labeled nanoparticles. , 2013, Molecular pharmaceutics.

[71]  C. Esmon,et al.  Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis. , 2012, Blood.

[72]  Lei Jiang,et al.  Study of uptake kinetics of vincristine for human erythrocytes by capillary zone electrophoresis with electrochemical detection , 2002 .

[73]  A. Corti,et al.  Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. , 2005, Cancer research.

[74]  Ronnie H. Fang,et al.  Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. , 2013, Nanoscale.

[75]  R. Hynes,et al.  Therapeutic expression of the platelet-specific integrin, αIIbβ3, in a murine model for Glanzmann thrombasthenia , 2005 .

[76]  Juan Fang,et al.  Intravenous Immunoglobulin (IVIG) Diminishes Immune-Mediated Clearance of Platelets Expressing an Integrin αIIbβ3 Transgene Product That Restores Hemostasis in a Canine Model for Glanzmann Thrombasthenia. , 2006 .

[77]  Liangfang Zhang,et al.  Erythrocyte‐Inspired Delivery Systems , 2012, Advanced healthcare materials.

[78]  Seungju M. Yu,et al.  Nanoparticle-assisted visualization of binding interactions between collagen mimetic peptide and collagen fibers. , 2006, Angewandte Chemie.

[79]  Xiaoqi Sun,et al.  Multifunctional Theranostic Red Blood Cells For Magnetic‐Field‐Enhanced in vivo Combination Therapy of Cancer , 2014, Advanced materials.

[80]  T. Wong,et al.  The reversible binding of vinblastine to platelets: implications for therapy. , 1981, Blood.

[81]  D. Atochin,et al.  Cerebrovascular Thromboprophylaxis in Mice by Erythrocyte-Coupled Tissue-Type Plasminogen Activator , 2008, Circulation.

[82]  F. Mayer,et al.  Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer , 2010, Clinical & Experimental Metastasis.

[83]  Scott L Diamond,et al.  Fibrin Affinity of Erythrocyte-Coupled Tissue-Type Plasminogen Activators Endures Hemodynamic Forces and Enhances Fibrinolysis in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.

[84]  E. Choi,et al.  Immunocytes as a biocarrier to delivery therapeutic and imaging contrast agents to tumors , 2012 .

[85]  K. Ley,et al.  Molecular mechanisms of leukocyte recruitment in the inflammatory process. , 1996, Cardiovascular research.

[86]  S. Peters,et al.  A microassay for Gaucher's disease. , 1975, Clinica chimica acta; international journal of clinical chemistry.

[87]  Michal Afri,et al.  NMR-based molecular ruler for determining the depth of intercalants within the lipid bilayer Part II. The preparation of a molecular ruler. , 2008, Chemistry and physics of lipids.

[88]  E. V. Kulikova,et al.  Doxorubicin pharmacokinetics in lymphoma patients treated with doxorubicin-loaded eythrocytes. , 2007, Haematologica.

[89]  V. Muzykantov,et al.  Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. , 1996, Analytical biochemistry.

[90]  C. Cinti,et al.  Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds , 2011, PloS one.

[91]  Ronnie H. Fang,et al.  Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release. , 2013, Nanomedicine.

[92]  V. Muzykantov,et al.  Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[93]  G P Samokhin,et al.  Target-sensitive immunoerythrocytes: interaction of biotinylated red blood cells with immobilized avidin induces their lysis by complement. , 1996, Biochimica et biophysica acta.

[94]  C. Ek,et al.  Changes in blood–brain barrier permeability to large and small molecules following traumatic brain injury in mice , 2007, The European journal of neuroscience.

[95]  Samir Mitragotri,et al.  Cell‐Based Drug Delivery Devices Using Phagocytosis‐Resistant Backpacks , 2011, Advanced materials.

[96]  J. Italiano,et al.  Platelets: production, morphology and ultrastructure. , 2012, Handbook of experimental pharmacology.

[97]  R. Hillman,et al.  Red cell manual , 1974 .

[98]  M. King,et al.  Leukocytes as carriers for targeted cancer drug delivery , 2015, Expert opinion on drug delivery.

[99]  J. Sixma,et al.  Human blood platelet adhesion to artery subendothelium is mediated by factor VIII–Von Willebrand factor bound to the subendothelium , 1979, Nature.

[100]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[101]  P. Ray,et al.  Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. , 2012, Cellular signalling.

[102]  V. Muzykantov,et al.  Advanced drug delivery systems for antithrombotic agents. , 2013, Blood.

[103]  E. Jessop.  Quality monitoring in the English National Health Service , 2014, Orphanet Journal of Rare Diseases.

[104]  A. Ellington,et al.  Directed evolution of gold nanoparticle delivery to cells. , 2010, Chemical communications.

[105]  L. Borsig,et al.  Selectins promote tumor metastasis. , 2010, Seminars in cancer biology.

[106]  K. Peter,et al.  Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding? , 2013, Blood.

[107]  F. Alanazi,et al.  Erythrocyte-mediated delivery of pravastatin: In Vitro study of effect of hypotonic lysis on biochemical parameters and loading efficiency , 2012, Archives of Pharmacal Research.

[108]  D. Irvine,et al.  Freely Suspended Cellular “Backpacks” Lead to Cell Aggregate Self-Assembly , 2010, Biomacromolecules.

[109]  F. Alanazi,et al.  Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel. , 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[110]  I R Edwards,et al.  Harmonisation in Pharmacovigilance , 1994, Drug safety.

[111]  R. Hynes,et al.  Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. , 2005, Blood.

[112]  R. Montgomery,et al.  Lentivirus‐mediated platelet‐derived factor VIII gene therapy in murine haemophilia A , 2007, Journal of thrombosis and haemostasis : JTH.

[113]  D. Lewis,et al.  Encapsulation of drugs in intact erythrocytes: an intravenous delivery system. , 1983, Biochemical pharmacology.

[114]  M. Magnani,et al.  Erythrocytes as a novel delivery vehicle for biologics: from enzymes to nucleic acid-based therapeutics. , 2012, Therapeutic delivery.

[115]  Rajbir Singh,et al.  Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies , 2014, Expert opinion on drug delivery.

[116]  H. Kantarjian,et al.  Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. , 2013, Protein and peptide letters.

[117]  N. Udupa,et al.  Erythrocytes as carrier for prednisolone: in vitro and in vivo evaluation. , 2010, Pakistan journal of pharmaceutical sciences.

[118]  Mehrdad Hamidi,et al.  Carrier erythrocytes: recent advances, present status, current trends and future horizons , 2014, Expert opinion on drug delivery.

[119]  A. Savoia,et al.  Inherited thrombocytopenias: from genes to therapy. , 2002, Haematologica.

[120]  L. Naldini,et al.  Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy? , 2009, Biochimica et biophysica acta.

[121]  Vladimir Muzykantov,et al.  Nanocarriers for vascular delivery of antioxidants. , 2011, Nanomedicine.

[122]  M. Magnani,et al.  Preparation and characterization of biotinylated red blood cells , 1994, Biotechnology and applied biochemistry.

[123]  N. Fiotti,et al.  Improving siRNA bio-distribution and minimizing side effects. , 2011, Current drug metabolism.

[124]  C. Bode,et al.  Targeting Ligand-Induced Binding Sites on GPIIb/IIIa via Single-Chain Antibody Allows Effective Anticoagulation Without Bleeding Time Prolongation , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[125]  Mehrdad Hamidi,et al.  Applications of carrier erythrocytes in delivery of biopharmaceuticals. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[126]  René M. Botnar,et al.  Magnetic conjugated polymer nanoparticles as bimodal imaging agents. , 2010, Journal of the American Chemical Society.

[127]  Mauro Magnani,et al.  Drug delivery by red blood cells , 2011, IUBMB life.

[128]  M. Muqit,et al.  CARRIER ERYTHROCYTE ENTRAPPED THYMIDINE PHOSPHORYLASE THERAPY FOR MNGIE , 2008, Neurology.

[129]  U. Sekhon,et al.  Targeted killing of metastatic cells using a platelet- inspired drug delivery system , 2015 .

[130]  J. Weisel,et al.  Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent. , 2011, Blood.

[131]  D. Wagner,et al.  How platelets safeguard vascular integrity , 2011, Journal of thrombosis and haemostasis : JTH.

[132]  Cheol Moon,et al.  L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[133]  M. Magnani,et al.  New Strategies to Prolong the In Vivo Life Span of Iron-Based Contrast Agents for MRI , 2013, PloS one.

[134]  T. Brunner,et al.  TRAIL‐Induced Apoptosis , 2009, Annals of the New York Academy of Sciences.

[135]  Ralph Weissleder,et al.  Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications , 2008, Basic Research in Cardiology.

[136]  Gregory P Howard,et al.  A platelet-mimetic paradigm for metastasis-targeted nanomedicine platforms. , 2013, Biomacromolecules.

[137]  R. Montgomery,et al.  Platelets as delivery systems for disease treatments. , 2010, Advanced drug delivery reviews.

[138]  Xingzhong Zhao,et al.  Core-shell supramolecular gelatin nanoparticles for adaptive and "on-demand" antibiotic delivery. , 2014, ACS nano.

[139]  K. Konstantopoulos,et al.  Biophysics of selectin–ligand interactions in inflammation and cancer , 2011, Physical biology.

[140]  M. Hamidi,et al.  Preparation and in vitro evaluation of carrier erythrocytes for RES-targeted delivery of interferon-alpha 2b. , 2007, International journal of pharmaceutics.

[141]  G. Brownlee,et al.  Subcutaneous injection of factor IX for the treatment of haemophilia B , 1992, British journal of haematology.

[142]  B. El-Gamal,et al.  Effect of platelet encapsulated Iloprost on platelet aggregation and adhesion to collagen and injured blood vessels in vitro. , 1992, Thrombosis and haemostasis.

[143]  C. Rothschild,et al.  Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A , 2005, Thrombosis and Haemostasis.

[144]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[145]  Vladimir R Muzykantov,et al.  Targeting of a Mutant Plasminogen Activator to Circulating Red Blood Cells for Prophylactic Fibrinolysis , 2010, Journal of Pharmacology and Experimental Therapeutics.

[146]  R. Flaumenhaft,et al.  Platelet alpha-granules: basic biology and clinical correlates. , 2009, Blood reviews.

[147]  Ronnie H. Fang,et al.  Engineered nanoparticles mimicking cell membranes for toxin neutralization. , 2015, Advanced drug delivery reviews.

[148]  Sang Joon Lee,et al.  Gold nanoparticle-incorporated human red blood cells (RBCs) for X-ray dynamic imaging. , 2011, Biomaterials.

[149]  Francesco Stellacci,et al.  Influence of the glycocalyx and plasma membrane composition on amphiphilic gold nanoparticle association with erythrocytes. , 2015, Nanoscale.

[150]  Sungmun Lee.  Monocytes: a novel drug delivery system targeting atherosclerosis , 2014, Journal of drug targeting.

[151]  Ronnie H. Fang,et al.  Nanoparticle biointerfacing via platelet membrane cloaking , 2015, Nature.